Design of a broad-range bacteriophage cocktail that reduces pseudomonas aeruginosa biofilms and treats acute infections in two animal models

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 6, 2018, Pages

  Forti, Francesca ^a   Roach, Dwayne R ^b   Cafora, Marco ^a   Pasini, Maria E ^a   Horner, David S ^a   Fiscarelli, Ersilia V ^c   Rossitto, Martina ^c   Cariani, Lisa ^a   Briani, Federica ^a   Debarbieux, Laurent ^b   Ghisotti, Daniela ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INSTITUT PASTEUR   (France)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Bacteriophages; Cystic fibrosis; Galleria mellonella; Phage therapy; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERIOPHAGE; BIOFILM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; FEMALE; GALLERIA MELLONELLA; GENETIC VARIABILITY; HOST RANGE; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGE; RESPIRATORY TRACT INFECTION; ANIMAL; LARVA; MICROBIOLOGY; MOTH; PATHOGENICITY; PHAGE THERAPY; PHYSIOLOGY; PROCEDURES; PSEUDOMONAS INFECTION; VIROLOGY;

ANIMALS; BACTERIOPHAGES; BIOFILMS; CYSTIC FIBROSIS; LARVA; MOTHS; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES;

EID: 85047635775     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02573-17     Document Type: Article

References (50)

1. Loc-Carrillo C, Abedon S. 2011. Pros and cons of phage therapy. Bacteriophage 1:111–114. https://doi.org/10.4161/bact.1.2.14590.
2. Roach DR, Debarbieux L. 2017. Phage therapy: awakening a sleeping giant. Emerg Top Life Sci 1:93–103. https://doi.org/10.1042/ETLS20170002.
3. D’Herelle F. 2017. On an invisible microbe antagonistic to dysenteric bacilli. C R Acad Sci 165:373–375.
4. Chibani-Chennoufi S, Bruttin A, Brüssow H, Dillmann M, Bru H. 2004. Phage-host interaction: an ecological perspective. J Bacteriol 186: 3677–3686. https://doi.org/10.1128/JB.186.12.3677-3686.2004.
5. Bruttin A, Brüssow H, Bru H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874–2878. https://doi.org/10.1128/AAC.49.7.2874-2878.2005.
6. Dufour N, Debarbieux L, Fromentin M, Ricard JD. 2015. Treatment of highly virulent extraintestinal pathogenic Escherichia coli pneumonia with bacteriophages. Crit Care Med 43:e190–e198. https://doi.org/10.1097/CCM.0000000000000968.
7. Chattopadhyay MK, Chakraborty R, Grossart H-P, Reddy GS, Jagannad-ham MV. 2015. Antibiotic resistance of bacteria. Biomed Res Int 2015: 1–2. https://doi.org/10.1155/2015/501658.
8. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317–327. https://doi.org/10.1038/nrmicro2315.
9. Denou E, Bruttin A, Barretto C, Ngom-Bru C, Brüssow H, Zuber S. 2009. T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388:21–30. https://doi.org/10.1016/j.virol.2009.03.009.
10. Cao F, Wang X, Wang L, Li Z, Che J, Wang L, Li X, Cao Z, Zhang J, Jin L, Xu Y. 2015. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int 2015:752930. https://doi.org/10.1155/ 2015/752930.
11. Wang Y, Mi Z, Niu W, An X, Yuan X, Liu H, Li P, Liu Y, Feng Y, Huang Y, Zhang X, Zhang Z, Fan H, Peng F, Tong Y, Bai C. 2016. Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia. Future Microbiol 11:631–641. https://doi.org/10.2217/fmb.16.11.
12. Fukuda K, Ishida W, Uchiyama J, Rashel M, Kato S-I, Morita T, Muraoka A, Sumi T, Matsuzaki S, Daibata M, Fukushima A. 2012. Pseudomonas aeruginosa keratitis in mice: effects of topical bacteriophage KPP12 administration. PLoS One 7:e47742. https://doi.org/10.1371/journal.pone.0047742.
13. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 201:1096–1104. https://doi.org/10.1086/651135.
14. Alemayehu D, Casey PG, McAuliffe O. 2012. Bacteriophages MR299-2 and NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway. mBio 3:e00029-12. https://doi.org/10.1128/mBio.00029-12.
15. Roach DR, Leung CY, Henry M, Morello E, Singh D, Di Santo JP, Weitz JS, Debarbieux L. 2017. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22:38–47. https://doi.org/10.1016/j.chom.2017.06.018.
16. Olszak T, Zarnowiec P, Kaca W, Danis-Wlodarczyk K, Augustyniak D, Drevinek P, de Soyza A, McClean S, Drulis-Kawa Z. 2015. In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients. Appl Microbiol Biotechnol 99:6021– 6033. https://doi.org/10.1007/s00253-015-6492-6.
17. Gill JJ, Hyman P. 2010. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 11:2–14. https://doi.org/10.2174/138920110790725311.
18. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, Van den Mooter G, Buckling A, Debarbieux L, Pouillot F, Azeredo J, Kutter E, Dublanchet A, Górski A, Adamia R. 2011. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm Res 28:934–937. https://doi.org/10.1007/s11095-010-0313-5.
19. Leplae R, Lima-Mendez G, Toussaint A. 2010. ACLAME: a classification of mobile genetic elements, update 2010. Nucleic Acids Res 38:D57–D61. https://doi.org/10.1093/nar/gkp938.
20. Holloway BW, Krishnapillai V, Morgan AF. 1979. Chromosomal genetics of Pseudomonas. Microbiol Rev 43:73–102.
21. Henry M, Lavigne R, Debarbieux L. 2013. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 57:5961–5968. https://doi.org/10.1128/AAC.01596-13.
22. Henry M, Bobay LM, Chevallereau A, Saussereau E, Ceyssens PJ, Debarbieux L. 2015. The search for therapeutic bacteriophages uncovers one new subfamily and two new genera of Pseudomonas-infecting Myoviridae. PLoS One 10:e0117163. https://doi.org/10.1371/journal.pone.0117163.
23. Goodridge LD. 2010. Designing phage therapeutics. Curr Pharm Biotechnol 11:15–27. https://doi.org/10.2174/138920110790725348.
24. Hall AR, De Vos D, Friman VP, Pirnay JP, Buckling A. 2012. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl Environ Microbiol 78:5646 –5652. https://doi.org/10.1128/AEM.00757-12.
25. Lacqua A, Wanner O, Colangelo T, Martinotti MG, Landini P. 2006. Emergence of biofilm-forming subpopulations upon exposure of Escherichia coli to environmental bacteriophages. Appl Environ Microbiol 72:956–959. https://doi.org/10.1128/AEM.72.1.956-959.2006.
26. Lin DM, Koskella B, Lin HC. 2017. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8:162–173. https://doi.org/10.4292/wjgpt.v8.i3.162.
27. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage 1:66–85. https://doi.org/10.4161/bact.1.2.15845.
28. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769–783. https://doi.org/10.2217/fmb.13.47.
29. Cooper CJ, Mirzaei MK, Nilsson AS. 2016. Adapting drug approval pathways for bacteriophage-based therapeutics. Front Microbiol 7:1209. https://doi.org/10.3389/fmicb.2016.01209.
30. Jennes S, Merabishvili M, Soentjens P, Pang KW, Rose T, Keersebilck E, Soete O, François PM, Teodorescu S, Verween G, Verbeken G, De Vos D, Pirnay JP. 2017. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury—a case report. Crit Care 21:129. https://doi.org/10.1186/s13054-017-1709-y.
31. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T. 2017. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother 61:e00954-17. https://doi.org/10.1128/AAC.00954-17.
32. Hizi A, Herzig E. 2015. dUTPase: the frequently overlooked enzyme encoded by many retroviruses. Retrovirology 12:70. https://doi.org/10.1186/s12977-015-0198-9.
33. Warner HR, Thompson RB, Mozer TJ, Duncan BK. 1979. The properties of a bacteriophage T5 mutant unable to induce deoxyuridine 5=-triphosphate nucleotidohydrolase. Synthesis of uracil-containing T5 de-oxyribonucleic acid. J Biol Chem 254:7534–7539.
34. Rakhuba DV, Kolomiets EI, Dey ES, Novik GI. 2010. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol 59:145–155.
35. Head NE, Yu H. 2004. Cross-sectional analysis of clinical and environmental isolates of Pseudomonas aeruginosa: biofilm formation, virulence, and genome diversity. Infect Immun 72:133–144. https://doi.org/10.1128/IAI.72.1.133-144.2004.
36. Dufour N, Clermont O, La Combe B, Messika J, Dion S, Khanna V, Denamur E, Ricard JD, Debarbieux L, Eveillard M, Kouatchet A, Lasocki S, Asfar P, Billard-Pomares T, Magdoud F, Barnaud G, Corvec S, Lakhal K, Armand L, Wolff M, Bourdon S, Reignier J, Martin S, Fihman V, Deprost N, Bador J, Charles PE, Goret J, Boyer A, Wallet F, Jaillette E, Nseir S, Landraud L, Ruimy R, Danin PE, Dellamonica J, Cremniter J, Frat JP, Jauréguy F, Clec’h C, Decré D, Maury E. 2016. Bacteriophage LM33_P1, a fast-acting weapon against the pandemic ST131-O25b:H4 Escherichia coli clonal complex. J Antimicrob Chemother 71:3072–3080. https://doi.org/10.1093/jac/dkw253.
37. Merabishvili M, Pirnay JP, De Vos D. 2018. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol Biol 1693:99–110. https://doi.org/10.1007/978-1-4939-7395-8_9.
38. Minandri F, Imperi F, Frangipani E, Bonchi C, Visaggio D, Facchini M, Pasquali P, Bragonzi A, Visca P. 2016. Role of iron uptake systems in Pseudomonas aeruginosa virulence and airway infection. Infect Immun 84:2324–2335. https://doi.org/10.1128/IAI.00098-16.
39. Adams M. 1959. Bacteriophages. Interscience Publishers, Inc., New York, NY.
40. Betts A, Vasse M, Kaltz O, Hochberg ME. 2013. Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol Appl 6:1054–1063. https://doi.org/10.1111/eva.12085.
41. Boulanger P. 2009. Purification of bacteriophages and SDS-PAGE analysis of phage structural proteins from ghost particles. Methods Mol Biol 502:227–238. https://doi.org/10.1007/978-1-60327-565-1_13.
42. Ghisotti D, Chiaramonte R, Forti F, Zangrossi S, Sironi G, Dehò G. 1992. Genetic analysis of the immunity region of phage-plasmid P4. Mol Microbiol 6:3405–3413. https://doi.org/10.1111/j.1365-2958.1992.tb02208.x.
43. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114–2120. https://doi.org/10.1093/bioinformatics/btu170.
44. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021.
45. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M, Mulvey MR, O’Brien JS, Pawlowski AC, Piddock LJV, Spanogiannopoulos P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright GD. 2013. The comprehensive antibiotic resistance database. Antimicrob Agents Chemother 57:3348–3357. https://doi.org/10.1128/ AAC.00419-13.
46. Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, Jin Q. 2005. VFDB: a reference database for bacterial virulence factors. Nucleic Acids Res 33(Database issue):D325–D328.
47. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215:403–410. https://doi.org/10.1016/S0022-2836(05)80360-2.
48. Kropinski AM, Prangishvili D, Lavigne R. 2009. Position paper: the creation of a rational scheme for the nomenclature of viruses of Bacteria and Archaea. Environ Microbiol 11:2775–2777. https://doi.org/10.1111/j .1462-2920.2009.01970.x.
49. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. 2010. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5:e10777. https://doi.org/10.1371/journal.pone.0010777.
50. Munder A, Wölbeling F, Klockgether J, Wiehlmann L, Tümmler B. 2014. In vivo imaging of bioluminescent Pseudomonas aeruginosa in an acute murine airway infection model. Pathog Dis 72:74–77. https://doi.org/10.1111/2049-632X.12184.